Form 4 Filing for Assembly Biosciences, Inc. - Officer Stock Acquisition

This filing details a Form 4 submitted by Jason A. Okazaki, CEO and President of Assembly Biosciences, Inc. (ASMB), on March 31, 2026. The report covers transactions on March 29, 2026, where Mr. Okazaki acquired 94,250 shares of Common Stock through a grant of restricted stock units (RSUs). The RSUs vest in four equal installments through March 29, 2030. Notably, these RSUs represent 65% of his annual equity grant, with the remaining 35% contingent upon stockholder approval of an amendment to the company's stock incentive plan. The acquisition was made at a price of $0.0 per share. Following this transaction, Mr. Okazaki holds 111,916 shares. The filing also notes the acquisition of 2,909 shares under the company's Employee Stock Purchase Plan on May 14, 2025.